Visikol

Executive Summary

Visikol is a privately held company headquartered in Whitehouse Station, New Jersey, specializing in advanced in vitro models for drug discovery and toxicity testing. Founded in 2014 and operating at the intersection of digital health and AI/machine learning, the company offers two flagship products: a novel blood-brain barrier (BBB) permeability assay employing a proprietary in vitro model, and the HUREL portfolio of primary hepatocyte micro livers, which covers over ten animal species. These platforms enable pharmaceutical researchers to assess the penetration kinetics of molecules across the BBB and to evaluate hepatotoxicity and metabolism in a physiologically relevant context, reducing reliance on animal testing and accelerating preclinical development. With its focus on high-fidelity organotypic models, Visikol addresses critical bottlenecks in CNS drug development and liver safety assessment. The BBB assay, in particular, helps predict brain exposure of drug candidates, while the hepatocyte models support species-specific toxicology studies. Although the company has not disclosed its funding or valuation, its integration of AI/ML tools suggests potential for data-driven insights. As the industry shifts toward more predictive in vitro systems, Visikol is well-positioned to capture demand from biopharma and CRO partners. Key near-term catalysts include the expansion of its HUREL model library, new collaborations with major pharmaceutical companies, and potential adoption of its BBB assay for high-throughput screening.

Upcoming Catalysts (preview)

• Q3 2026Launch of additional animal species in HUREL hepatocyte portfolio70% success
• Q4 2026Strategic partnership with a top 20 pharma company for BBB assay validation50% success
• 2027Adoption of AI-enhanced analytics for high-throughput screening40% success